Sold as Alfenta. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Alfentanil Hydrochloride (sold as Alfenta), first approved Dec 29, 1986, with 1 new use approved and 0 published complete response letters.
| Determination of ED90 of Remimazolam Besylate Combined With Alfentanil for Gastroscopy Sedation in Obese PatientsProcedural Sedation and Analgesia, Obesity & Overweight · Jianbo Wu | Not applicable | Recruiting | Nov 9, 2026 |
| Afentanil and Remifentanil for Anesthesia Quality and RecoveryAnesthesia Recovery Period ； Postoperative Pain； Hemodynamic Stability During Surgery · Qianfoshan Hospital | Phase 4 | Not yet recruiting | Aug 12, 2026 |
| A Study to Evaluate the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection in Participants With Moderate-to-Severe Non-Cancer Chronic PainChronic Pain · The Third Xiangya Hospital of Central South University | Phase 1 | Not yet recruiting | Aug 7, 2026 |
| Remimazolam for Bronchoscopy in High-Risk PatientsPulmonary Infection, Pulmonary Nodule · First Affiliated Hospital of Zhejiang University | Phase 4 | Recruiting | Feb 9, 2026 |
| A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic SurgeryThoracic Surgery, Anesthesia · The First Affiliated Hospital of Xinxiang Medical College | Phase 4 | Not yet recruiting | Jan 16, 2026 |
| EEG and Pain Monitor Data Under Anesthesia to Study Pharmacodynamic Effects of Opioids and SedativesSedation and Analgesia, Cholangiopancreatography, Endoscopic Retrograde · Chi Kwan Fung | Not applicable | Recruiting | Oct 8, 2025 |
| Dec 29, 1986 | AlfentaNDA 19353 · New molecular entity | Rising | 20 | Marketed |
| Oct 28, 1999 | AlfentanilANDA 75221 | Hospira | 6 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
